BIO Innovation Zone Company Snapshots: GlycoMira Therapeutics, TheraSource, and Biomedica Management
Later this month in Philadelphia at the BIO International Convention, BIO will be partnering with the National Institutes of Health (NIH) and the National Science Foundation (NSF) to host the 2nd annual, newly-expanded BIO Innovation Zone. The Zone will feature Small Business Innovation Research (SBIR) funded early-stage biotech companies.
The SBIR/STTR program provides U.S. federal funding to small businesses engaged in research with the potential for commercialization. Each of the companies has been rigorously vetted through the SBIR/STTR review process prior to receiving the non-dilutive funding to engage in R&D that has the potential for commercialization. The NIH and NSF invest a combined $940 million annually in the programs.
Today, we spoke with Justin Savage, the Director of Operations atGlycoMira Therapeutics based in Salt Lake City, Utah, Weng-Lang Yang, the Chief Scientific Officer of TheraSource LLC in Manhasset, New York and George Falus, CEO of Biomedica Management. These three biotechnology companies have been supported by the NIH’s SBIR program.
